Vascular Biogenics Ltd., of Tel Aviv, Israel, said it has agreed to sell and issue approximately 4.36 million ordinary shares to institutional investors in the U.S. at $5.50 per share in a registered direct offering with gross proceeds of approximately $24 million. Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the exclusive placement agent for the registered direct offering.